Peter Leddy - Maravai Lifesciences Executive Officer

MRVI Stock  USD 5.93  0.50  9.21%   

Executive

Peter Leddy is Executive Officer of Maravai Lifesciences Holdings
Age 61
Address 10770 Wateridge Circle, San Diego, CA, United States, 92121
Phone858 546 0004
Webhttps://www.maravai.com

Maravai Lifesciences Management Efficiency

The company has return on total asset (ROA) of (0.0161) % which means that it has lost $0.0161 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4293) %, meaning that it created substantial loss on money invested by shareholders. Maravai Lifesciences' management efficiency ratios could be used to measure how well Maravai Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. The Maravai Lifesciences' current Return On Tangible Assets is estimated to increase to -0.12. The Maravai Lifesciences' current Return On Capital Employed is estimated to increase to -0.02. As of now, Maravai Lifesciences' Intangibles To Total Assets are decreasing as compared to previous years. The Maravai Lifesciences' current Debt To Assets is estimated to increase to 0.46, while Total Assets are projected to decrease to under 1.5 B.
Maravai Lifesciences Holdings currently holds 610.97 M in liabilities with Debt to Equity (D/E) ratio of 0.69, which is about average as compared to similar companies. Maravai Lifesciences has a current ratio of 7.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Maravai Lifesciences' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Andy DeigImmunovant
N/A
Alan KickLegend Biotech Corp
N/A
PharmD MBAIncyte
66
Alison SkrinarUltragenyx
54
Diane WeiserCytokinetics
N/A
Amy MaheryRoivant Sciences
47
John SchembriAkero Therapeutics
62
David ChienKrystal Biotech
N/A
Caroline MDApellis Pharmaceuticals
57
Mohammad MasjedizadehProtagonist Therapeutics
N/A
Ram KamineniKrystal Biotech
N/A
Steven MDIncyte
57
Clive PatienceAgios Pharm
60
Matthew GoslingProtagonist Therapeutics
53
Paula SwainIncyte
66
Carter KingProtagonist Therapeutics
53
Scott GangloffAkero Therapeutics
50
Christian UlrichHarmony Biosciences Holdings
N/A
Nyssa NoyolaAscendis Pharma AS
N/A
Lauren MBAImmunovant
N/A
Paul JDUltragenyx
N/A
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California. Maravai LifeSciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 470 people. Maravai Lifesciences Holdings (MRVI) is traded on NASDAQ Exchange in USA. It is located in 10770 Wateridge Circle, San Diego, CA, United States, 92121 and employs 580 people. Maravai Lifesciences is listed under Life Sciences Tools & Services category by Fama And French industry classification.

Management Performance

Maravai Lifesciences Leadership Team

Elected by the shareholders, the Maravai Lifesciences' board of directors comprises two types of representatives: Maravai Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Maravai. The board's role is to monitor Maravai Lifesciences' management team and ensure that shareholders' interests are well served. Maravai Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Maravai Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Kurt Oreshack, General VP
Christine Dolan, Executive Technologies
Brian Neel, Chief Production
Peter Leddy, Executive Officer
Carl Hull, CoFounder Chairman
Christopher Benoit, Executive Enzymes
Becky Buzzeo, Executive Officer
Kate Broderick, Chief Officer
Andrew Burch, President Production
Rebecca Buzzeo, Executive Officer
Debra Hart, Director Relations
Doreen Pippen, VP Marketing
William III, Chief Officer
Kevin Herde, Executive CFO
Kevin CPA, Executive CFO
Kurt JD, General VP

Maravai Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Maravai Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Maravai Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Maravai Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maravai Lifesciences Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maravai Lifesciences Holdings Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.33)
Earnings Share
(1.67)
Revenue Per Share
2.044
Quarterly Revenue Growth
(0.03)
Return On Assets
(0.02)
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.